All In Biotech

Drug Trial Radar · NCT04878471

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

A Phase 1 Single Intravenous Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

Last checked: Nov 20, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jun 2, 2021

Primary completion

Jul 22, 2021

Study completion Jul 22, 2021

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
May 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Male only, from 20 years, up to 44 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single intravenous doses of ASP5354 in healthy, adult Japanese male participants.

Conditions

  • Healthy Volunteers

Interventions

  • Pudexacianinium chlorideDrug

    Intravenous

  • PlaceboDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: Up to 6 days
  2. Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 6 days
  3. Number of participants with vital sign abnormalities and/or adverse events (AEs)Time frame: Up to 6 days
  4. Number of participants with routine 12-lead electrocardiogram (ECG) abnormalities and/or adverse events (AEs)Time frame: Up to 6 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • JP81001

    Sumida-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.